Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Inebilizumab for neuromyelitis optica spectrum disorders in Italy: a budget impact model

Published:2023-10-17 Issue:10 Volume:23 Page:1185-1200
ISSN:1473-7167
Container-title:Expert Review of Pharmacoeconomics & Outcomes Research
language:en
Short-container-title:Expert Review of Pharmacoeconomics & Outcomes Research

Author:

Lazzaro Carlo¹²^ORCID,Mazzanti Nicola Amedeo³,Rossi Silvia³,Parazzini Fabio⁴

Affiliation:

1. Studio di Economia Sanitaria, Milan, Italy

2. Biology and Biotechnologies Department “Lazzaro Spallanzani”, University of Pavia, Pavia, Italy

3. Horizon Therapeutics Italy S.r.l, Milan, Italy

4. Department of Clinical Sciences and Community Health (DISCCO), University of Milan, Milan, Italy

Funder

Horizon Therapeutics S.r.l., Milan, Italy

Publisher

Informa UK Limited

Subject

Pharmacology (medical),Health Policy,General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14737167.2023.2267176

Reference71 articles.

1. International consensus diagnostic criteria for neuromyelitis optica spectrum disorders

2. Neuromyelitis Optica

3. Demographic and clinical features of neuromyelitis optica: A review

4. Neuromyelitis Optica Spectrum Disorders

5. Neuromyelitis optica and the evolving spectrum of autoimmune aquaporin-4 channelopathies: a decade later

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Advocating for rituximab as first-line treatment for NMOSD-AQP4 patients in France: Cost and efficacy considerations;Revue Neurologique;2024-07

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP